• Criptomoedas
  • Mercados de Previsão
  • Notícias
  • Trading Agêntico
  • Artigos
  • Ligas

Pesquisar Criptomoedas

Criptomoedas em tendência

CoinRithm

Empresa

Entidade legal
Bees-x Limited
Número da empresa
13308136
Constituída em
England and Wales
Sede registrada
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm é um serviço de informação e pesquisa operado pela Bees-x Limited. Não é autorizado pela Financial Conduct Authority (FCA) a realizar atividades reguladas, e nada neste site constitui aconselhamento financeiro.

Explorar

CriptomoedasMercados de PrevisãoNotíciasArtigosAgent ArenaLigas

Recursos

Painel de ControleComércio SimuladoTrading AgênticoCarteiraLista de ObservaçãoConfigurações

Empresa

Sobre NósMetodologiaTermos de UsoPolítica de PrivacidadePolítica de CookiesAviso Legal

Suporte

Apoio ao ClienteFAQKit para desenvolvedoresDocumentação MCP

Redes Sociais

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Direitos reservados.
Disponível no Google PlayBaixar na App Store
  • Início
  • MercadosMercados de Previsão
  • Notícias
  • Painel de Controle
  1. Mercados de Previsão
  2. Health & Medicine
  3. When will Intellia Therapeutics submit a BLA for Lonvo-z?
When will Intellia Therapeutics submit a BLA for Lonvo-z?

When will Intellia Therapeutics submit a BLA for Lonvo-z?

Health & MedicineOne-OffCiência2m
KalshiKalshiVerificar disponibilidadeKYC obrigatório2% de taxa
Probabilidade implícita atual
before September
before September 45%
Líder entre 6 opções
Qualidade do mercado

24 / 100

Baixa qualidade
Volume 24h

0 €

Liquidez

20,7 €

Baixa liquidez
Compra / Venda

35.0% / 45.0%

Spread

28.6%

Spread amplo
Dados do mercado

Atualizado há 4 minutos

24/03/26, 14:001/09/26, 14:00

Tendências

Resultado24hProbabilidade

Resultado escolhido

before September45%

Regras

If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Sep 1, 2026, then the market resolves to Yes.

Kalshi
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Oct 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Nov 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Dec 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Jan 1, 2027, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Apr 1, 2027, then the market resolves to Yes.

Mercados Relacionados

When will Beam Therapeutics submit a BLA for Risto-cel?

When will Beam Therapeutics submit a BLA for Risto-cel?

4,6 €
before April 2027: 72%KalshiKALSHI
When will Compass Pathways submit a NDA for COMP360 psilocybin?

When will Compass Pathways submit a NDA for COMP360 psilocybin?

0,3 €
before September: 31%KalshiKALSHI
Will there be a year without polio before 2030?

Will there be a year without polio before 2030?

0 €
Sim: 10%KalshiKALSHI
Which countries will have an Ebola case in 2026?

Which countries will have an Ebola case in 2026?

138,2 €
Uganda: 100%PolymarketPOLYMARKET
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

147,6 mil €
Sim: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16,6 mil €
Sim: 10%PolymarketPOLYMARKET

Ativos nestes tópicos

BitcoinBTC$62,835.25+1.92%EthereumETH$1,657.81+1.25%SolanaSOL$65.23+1.59%DogecoinDOGE$0.0851+1.38%XRPXRP$1.12+0.44%BNBBNB$601.79+2.49%

Notícias Relacionadas

Anthropic’s Claude Tackles Chemistry with NMR Structure AnalysisBlockchain.NewsChainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsQuantus’ Q-Day Brings Together Leading Cryptographers, Blockchain Builders, Investors, and Researchers to Prepare for the Post-Quantum FutureBlockchain ReporterOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.News

Regras

If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Sep 1, 2026, then the market resolves to Yes.

Kalshi
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Oct 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Nov 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Dec 1, 2026, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Jan 1, 2027, then the market resolves to Yes.
  • If Intellia Therapeutics, Inc. submits a BLA for Lonvoguran Ziclumeran (lonvo-z) to the FDA before Apr 1, 2027, then the market resolves to Yes.